isoproterenol has been researched along with mexiletine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brown, AM; Cantù, F; Napolitano, C; Priori, SG; Schwartz, PJ | 1 |
| Antzelevitch, C; Shimizu, W | 1 |
| Ishii, K; Karikomi, Y; Kubota, Y; Nakahara, T; Sakamoto, K | 1 |
| Cárdenas, M; Hermosillo, AG; Márquez, MF; Pastelín, G; Salica, G | 1 |
| Lane, JD; Montaigne, D; Tinker, A | 1 |
| Pfammatter, JP; Wåström, M | 1 |
2 review(s) available for isoproterenol and mexiletine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug therapy in Brugada syndrome.
Topics: Bundle-Branch Block; Cilostazol; Electrocardiography; Humans; Isoproterenol; Mexiletine; Sotalol; Syndrome; Tetrazoles | 2005 |
11 other study(ies) available for isoproterenol and mexiletine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Cation Transport Proteins; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Intercellular Signaling Peptides and Proteins; Isoproterenol; Long QT Syndrome; Mexiletine; Mutation; Peptides; Phenethylamines; Potassium Channels; Potassium Channels, Voltage-Gated; Receptors, Adrenergic, beta; Sodium Channel Blockers; Sodium Channels; Sulfonamides | 1996 |
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Isoproterenol; KCNQ Potassium Channels; Long QT Syndrome; Membrane Potentials; Mexiletine; Perfusion; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Sodium Channel Blockers; Torsades de Pointes | 1998 |
Characterization of mexiletine as an antagonist of beta-adrenoceptor in Chinese hamster ovary cells expressing cloned human beta-adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Drug Interactions; Female; Humans; Iodine Radioisotopes; Isoproterenol; Kinetics; Lidocaine; Mexiletine; Pindolol; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Transfection | 2004 |
Tissue-Level Cardiac Electrophysiology Studied in Murine Myocardium Using a Microelectrode Array: Autonomic and Thermal Modulation.
Topics: Animals; Atrial Function; Carbachol; Electrophysiologic Techniques, Cardiac; Electrophysiological Phenomena; Female; Heart Atria; Heart Ventricles; Isoproterenol; Male; Mexiletine; Mice; Microelectrodes; Myocardium; Ventricular Function | 2017 |
Ten-year-old boy with congenital long QT syndrome type 2 (LQTS2) and life-threatening electrical storm: a case report of successful treatment with mexiletine.
Topics: Arrhythmias, Cardiac; Humans; Isoproterenol; Long QT Syndrome; Male; Mexiletine; Ventricular Fibrillation | 2022 |